趋化因子CXCL16/CXCR6轴与乳腺癌相关关系的研究进展  

Research progress of CXCL16/CXCR6 axis in breast cancer

作　　者：周子婷 葛菲(综述) 蒋爱梅(审校)[1] ZHOU Zi-ting;GE Fei;JIANG Ai-mei(Department of Breast Surgery, the First Affiliated Hospital of Kunming Medical University, Yunnan 650032, China)

机构地区：[1]昆明医科大学第一附属医院乳腺外科,云南650032

出　　处：《中国临床新医学》2020年第6期631-635,共5页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

基　　金：国家自然科学基金项目(编号:81660438)。

摘　　要：乳腺癌是中老年女性发病率及病死率高居首位的恶性肿瘤,且呈年轻化趋势。乳腺癌发生、发展过程受诸多因素调控,其病因及发病机制尚未完全清楚。该文旨在对趋化因子CXCL16/CXCR6轴的结构、功能及其在乳腺癌发生、发展、侵袭过程中调控作用进行综述,为乳腺癌的分子生物学研究及靶向抗肿瘤治疗提供新思路。Breast cancer is a malignant tumor with the highest morbidity and mortality among middle-aged and elderly women,and the patients who get this cancer become younger and younger.The occurrence and development of breast cancer are regulated by many factors,and its etiology and pathogenesis are not completely clear.This paper aims to investigate the structure and function of the Chemokine(C-X-C motif)ligand 16(CXCL16)/C-X-C chemokine receptor type 6(CXCR6)axis and its regulatory role in the occurrence,development and invasion of breast cancer,and to provide a review of new ideas for molecular biological research and targeted anti-tumor therapy of breast cancer.

关 键 词：趋化因子 CXC型趋化因子配体16 细胞表面趋化因子受体6 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]